Results 261 to 270 of about 39,064 (303)

A Methodological Proposal for Health Technology Assessments: A Case Study on Biosimilar Drugs. [PDF]

J Mark Access Health Policy
Dimmito MP, Marinelli L, Toto EC, Di Biase G, Cacciatore I, Toto P, Ciulla M, Monti B, Santoleri F, Costantini A, Di Stefano A.   +10 more
europepmc   +1 more source

Biosimilars: Current regulatory perspective and challenges

, 2013
Diwakar Jha, Ram Kumar Mishra, Rishabh Deo Pandey   +2 more
openalex   +1 more source

Global Harmonization of Biosimilar Development by Overcoming Existing Differences in Regional Regulatory Requirements - Outcomes of a Descriptive Review. [PDF]

Ther Innov Regul Sci
Kirchlechner TM, Cohen HP.
europepmc   +1 more source

Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment. [PDF]

United European Gastroenterol J
D'Amico F, Bencardino S, Gonçalves A, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S.   +9 more
europepmc   +1 more source

Regulierung und adäquate Preisbildung im Markt der Biosimilars: Projekt im Auftrag der Pfizer Deutschland GmbH

, 2017
Altin, Sibel, Bauer, Cosima, May, Uwe, Walendzik, Anke, Wasem, Jürgen, Ziebe, Anissa   +5 more
core  

The Tailored Biosimilar Approach: Expectations and Requirements. [PDF]

Drugs
Guillen E, Barry S, Jost N, Ekman N, Knippel V, Kuhlmann-Gottke J, Maier J, Weise M, Laslop A, Anour R, van Zandbergen G, Kirsch-Stefan N.   +11 more
europepmc   +1 more source

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries. [PDF]

BMJ Open
Morolla D, Beran D, Ewen M, Raviglione M, von Schoen-Angerer T.   +4 more
europepmc   +1 more source

Patient characteristics and use for bevacizumab in ophthalmology and oncology in a distributed research network. [PDF]

J Manag Care Spec Pharm
Ko JS, Mendelsohn AB, Daniels K, Gomez-Lumbreras A, Marshall J, McDermott C, Pawloski PA, Yee GC, Lockhart CM.   +8 more
europepmc   +1 more source

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

, 2012
D. Kamioner, Stefan Früehauf, Frédéric Maloisel, L. Cals, Stéphane Leprêtre, Christian Berthou   +5 more
openalex   +1 more source

Accelerating biosimilar market access: the case for allowing earlier standing. [PDF]

J Law Biosci
Tu SS, Goode R, Turner M, Van de Wiele V.   +3 more
europepmc   +1 more source